PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS

Bibliographic Details
Main Authors:	E.Q. Crusoé, M.A. Salvino, S.Q. Silva, H.H.M. Santos, A.S. Santos, A.M. Almeida, L.O. Vieira, C.A. Fonseca, L.F. Lucas, J.S. Leal, M.M. Santos, J.A. Santos, E. Adorno, V.T.M. Hungria, M.G.B. Arruda
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137920307410

Similar Items

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS
by: EQ Crusoe, et al.
Published: (2021-10-01)

IMMUNE PROFILING EVALUATION OF NEWLY DIAGNOSE MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS TREATED WITH DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (DARA-CTD): PRELIMINARY RESULTS
by: A.S. Santos, et al.
Published: (2020-11-01)

IMPACT OF DARATUMUMAB (DARA) ADMINISTRATION DURING TRANSPLANT- ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) INDUCTION ON STEM CELL (SC) MOBILIZATION COUNT AND POST-TRANSPLANT ENGRAFTMENT
by: EQ Crusoe, et al.
Published: (2021-10-01)

EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS
by: A Santos, et al.
Published: (2021-10-01)

P24 HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M2 AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE
by: C. Liberatore, et al.
Published: (2023-05-01)

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: K. Groen, et al.
Published: (2022-06-01)

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)
by: H. Ludwig, et al.
Published: (2022-06-01)

SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
by: EQ Crusoe, et al.
Published: (2021-10-01)

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
by: T. Facon, et al.
Published: (2022-06-01)

Perinatal outcomes of quadruplet pregnancy
by: S. A. Kalashnikov, et al.
Published: (2021-09-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
by: K. Weisel, et al.
Published: (2023-05-01)

A RARE SPONTANEOUS QUADRUPLET PREGNANCY
by: A TAHERIAN, et al.
Published: (2003-12-01)

Construction and Performance Studies of Large Resistive Micromegas Quadruplets
by: Farina E., et al.
Published: (2018-01-01)

Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
by: Cheong Ngai, et al.
Published: (2021-09-01)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
by: Philippe Moreau, et al.
Published: (2021-02-01)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
by: M. I. Nuevo López, et al.
Published: (2022-06-01)

PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
by: Y. Li, et al.
Published: (2022-06-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
by: Juan José Gil‐Fernández, et al.
Published: (2024-01-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
by: Ajay K. Nooka, et al.
Published: (2022-04-01)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
by: Priscilla Cury de Camargo Cury, et al.
Published: (2020-04-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

Bandhead Energies of npp/pnn Three-Quasiparticle Quadruplets
by: Sushil Kumar, et al.
Published: (2023-02-01)

Engineering exclusively-quadruplet codon translation in vivo
by: DeBenedictis, Erika Alden.
Published: (2021)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
by: C. Touzeau, et al.
Published: (2022-06-01)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
by: I. Vaxman, et al.
Published: (2023-05-01)

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
by: A. Schavgoulidze, et al.
Published: (2022-06-01)

Analysis of the Status of Iranian Patents in Quadruplet Patent Offices
by: Mohammad Alaee Arani, et al.
Published: (2010-02-01)

Heterotopic Quadruplet Pregnancy. Literature Review and Case Report
by: Brîndușa Cimpoca, et al.
Published: (2021-05-01)

Video fingerprinting based on quadruplet convolutional neural network
by: Xinwei Li, et al.
Published: (2021-04-01)

Waveguide Quadruplet Diplexer for Multi-Beam Satellite Applications
by: Javier Ossorio Garcia, et al.
Published: (2020-01-01)

A Deep Quadruplet Network for Local Descriptor Learning
by: Xiaodong Wang, et al.
Published: (2020-01-01)

Successful Management of Quadruplet Pregnancy following Spontaneous Conception
by: Deepak Shrestha, et al.
Published: (2016-06-01)

The neonatal outcome in twin versus triplet and quadruplet pregnancies
by: Fatemeh Nasseri, et al.
Published: (2009-02-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
by: Marina Zajec, et al.
Published: (2020-08-01)

Ageing Studies on the First Resistive-MicroMeGaS Quadruplet at GIF++ Preliminary Results
by: Alvarez Gonzalez B., et al.
Published: (2018-01-01)

Adverse events in patients with leprosy on treatment with thalidomide
by: Paula Lana de Miranda Drummond, et al.
Published: (2019-04-01)

The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.
by: Soraya Machado de Jesus, et al.
Published: (2020-08-01)